---
figid: PMC2735334__nihms95693f5
figlink: /pmc/articles/PMC2735334/figure/F5/
number: F5
caption: Mechanisms of VEGF/VEGFR-mediated protection of cardiomyocytes from pressure
  stress and ischemia, and potential interactions of sunitinib and sorafenib. Hypertensive
  stress in the heart and the resulting relative ischemia/hypoxia of cardiomyocytes
  activate HIF-1, leading to the release of angiogenic factors including VEGF. VEGF
  activates VEGFRs on the surface of endothelial cells (EC), activating a number of
  pathways that induce vasodilation (NO and PGI2), EC proliferation and survival (Akt
  and ERKs), and the further release of proangiogenic factors, all of which lead to
  angiogenesis in the heart, allowing compensated hypertrophy to occur.,  Sunitinib
  and sorafenib inhibit VEGFRs in ECs, potentially blocking angiogenesis and leading
  to decompensated hypertrophy. Sunitinib, via an off-target effect, may also inhibit
  various cytoprotective pathways in the heart (e.g. RSK, which would otherwise inhibit
  pro-apoptotic Bad). Sorafenib, by inhibiting the Raf/ERK pathway, could also induce
  apoptosis in ECs and cardiomyocytes.
pmcid: PMC2735334
papertitle: Mechanisms of cardiomyopathy associated with tyrosine kinase inhibitor
  cancer therapeutics.
reftext: Ming Hui Chen, et al. Circulation. ;118(1):84-95.
pmc_ranked_result_index: '166089'
pathway_score: 0.8827238
filename: nihms95693f5.jpg
figtitle: VEGF/VEGFR-mediated protection of cardiomyocytes from pressure stress and
  ischemia, and potential interactions of sunitinib and sorafenib
year: ''
organisms: Homo sapiens
ndex: bdb842e0-df18-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC2735334__nihms95693f5.html
  '@type': Dataset
  description: Mechanisms of VEGF/VEGFR-mediated protection of cardiomyocytes from
    pressure stress and ischemia, and potential interactions of sunitinib and sorafenib.
    Hypertensive stress in the heart and the resulting relative ischemia/hypoxia of
    cardiomyocytes activate HIF-1, leading to the release of angiogenic factors including
    VEGF. VEGF activates VEGFRs on the surface of endothelial cells (EC), activating
    a number of pathways that induce vasodilation (NO and PGI2), EC proliferation
    and survival (Akt and ERKs), and the further release of proangiogenic factors,
    all of which lead to angiogenesis in the heart, allowing compensated hypertrophy
    to occur.,  Sunitinib and sorafenib inhibit VEGFRs in ECs, potentially blocking
    angiogenesis and leading to decompensated hypertrophy. Sunitinib, via an off-target
    effect, may also inhibit various cytoprotective pathways in the heart (e.g. RSK,
    which would otherwise inhibit pro-apoptotic Bad). Sorafenib, by inhibiting the
    Raf/ERK pathway, could also induce apoptosis in ECs and cardiomyocytes.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - BAD
  - ARAF
  - VEGFA
  - SETD2
  - AKT3
  - RAF1
  - BRAF
  - MAPK3
  - RPS6KB2
  - NOS3
  - VEGFD
  - RPS6KA6
  - AKT2
  - RPS6KA4
  - MAPK1
  - RPS6KA3
  - RPS6KB1
  - AKT1
  - RPS6KA5
  - VEGFC
  - RPS6KA1
  - VEGFB
  - RPS6KA2
  - PGF
  - Cancer
genes:
- word: Bad
  symbol: BAD
  source: hgnc_symbol
  hgnc_symbol: BAD
  entrez: '572'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFA
  entrez: '7422'
- word: HIF-1
  symbol: HIF-1
  source: hgnc_alias_symbol
  hgnc_symbol: SETD2
  entrez: '29072'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: RSK
  symbol: RSK
  source: bioentities_symbol
  hgnc_symbol: RPS6KB2
  entrez: '6199'
- word: ENOS
  symbol: eNOS
  source: hgnc_alias_symbol
  hgnc_symbol: NOS3
  entrez: '4846'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFD
  entrez: '2277'
- word: RSK
  symbol: RSK
  source: bioentities_symbol
  hgnc_symbol: RPS6KA6
  entrez: '27330'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: RSK
  symbol: RSK
  source: bioentities_symbol
  hgnc_symbol: RPS6KA4
  entrez: '8986'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: RSK
  symbol: RSK
  source: bioentities_symbol
  hgnc_symbol: RPS6KA3
  entrez: '6197'
- word: RSK
  symbol: RSK
  source: bioentities_symbol
  hgnc_symbol: RPS6KB1
  entrez: '6198'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: RSK
  symbol: RSK
  source: bioentities_symbol
  hgnc_symbol: RPS6KA5
  entrez: '9252'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFC
  entrez: '7424'
- word: RSK
  symbol: RSK
  source: bioentities_symbol
  hgnc_symbol: RPS6KA1
  entrez: '6195'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFB
  entrez: '7423'
- word: RSK
  symbol: RSK
  source: bioentities_symbol
  hgnc_symbol: RPS6KA2
  entrez: '6196'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: PGF
  entrez: '5228'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
figid_alias: PMC2735334__F5
redirect_from: /figures/PMC2735334__F5
figtype: Figure
---
